Incidence and prognostic significance of newly-diagnosed atrial fibrillation among older U.S. veterans hospitalized with COVID-19

• Published in: Scientific reports Vol. 14; no. 1; p. 952
• Main Authors: Ko, Darae, Treu, Timothy M., Tarko, Laura, Ho, Yuk-Lam, Preis, Sarah R., Trinquart, Ludovic, Gagnon, David R., Monahan, Kevin M., Helm, Robert H., Orkaby, Ariela R., Lubitz, Steven A., Bosch, Nicholas A., Walkey, Allan J., Cho, Kelly, Wilson, Peter W. F., Benjamin, Emelia J.
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 10.01.2024; Nature Publishing Group; Nature Portfolio
• Subjects: 692/499; 692/699/255/2514; 692/699/75/29/1309; Aged; Atrial Fibrillation - diagnosis; Atrial Fibrillation - epidemiology; Cardiac arrhythmia; Comorbidity; COVID-19; COVID-19 - epidemiology; Fibrillation; Hospitalization; Humanities and Social Sciences; Humans; Incidence; Medicare; Mortality; multidisciplinary; Patients; Primary care; Prognosis; Science; Science (multidisciplinary); United States - epidemiology; Veterans; United States
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-024-51177-6

Most prior studies on the prognostic significance of newly-diagnosed atrial fibrillation (AF) in COVID-19 did not differentiate newly-diagnosed AF from pre-existing AF. To determine the association between newly-diagnosed AF and in-hospital and 30-day mortality among regular users of Veterans Health Administration using data linked to Medicare. We identified Veterans aged ≥ 65 years who were hospitalized for ≥ 24 h with COVID-19 from 06/01/2020 to 1/31/2022 and had ≥ 2 primary care visits within 24 months prior to the index hospitalization. We performed multivariable logistic regression analyses to estimate adjusted risks, risk differences (RD), and odds ratios (OR) for the association between newly-diagnosed AF and the mortality outcomes adjusting for patient demographics, baseline comorbidities, and presence of acute organ dysfunction on admission. Of 23,299 patients in the study cohort, 5.3% had newly-diagnosed AF, and 29.2% had pre-existing AF. In newly-diagnosed AF adjusted in-hospital and 30-day mortality were 16.5% and 22.7%, respectively. Newly-diagnosed AF was associated with increased mortality compared to pre-existing AF (in-hospital: OR 2.02, 95% confidence interval [CI] 1.72–2.37; RD 7.58%, 95% CI 5.54–9.62) (30-day: OR 1.86; 95% CI 1.60–2.16; RD 9.04%, 95% CI 6.61–11.5) or no AF (in-hospital: OR 2.24, 95% CI 1.93–2.60; RD 8.40%, 95% CI 6.44–10.4) (30-day: 2.07, 95% CI 1.80–2.37; RD 10.2%, 95% CI 7.89–12.6). There was a smaller association between pre-existing AF and the mortality outcomes. Newly-diagnosed AF is an important prognostic marker for patients hospitalized with COVID-19. Whether prevention or treatment of AF improves clinical outcomes in these patients remains unknown.